Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements

2 years ago

LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved…

Surgalign Announces Release of HOLO™ AI Insights for Spine Imaging

2 years ago

Surgalign’s HOLO AI Insights aims to enhance clinical decision making through the power of AI technologyDEERFIELD, Ill., March 13, 2023…

iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023

2 years ago

Company is exploring strategic options for its Therapy business lineNASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD),…

Intelligent Bio Solutions Inc. Selects HASTA Laboratory as Drug Testing Specialist in Australia

2 years ago

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions" or the "Company") (Nasdaq: INBS),…

Healthcare Triangle Confirms No Exposure to Silicon Valley Bank

2 years ago

PLEASANTON, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the "Company"), a leading provider…

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

2 years ago

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company…

Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023

2 years ago

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,…

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

2 years ago

Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to…

Senior Financial Executive Judy Bjornaas Elected to DLH Board of Directors

2 years ago

ATLANTA, March 13, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of…

Windtree Regains Compliance with Nasdaq

2 years ago

WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…